Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative.
Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, Krainc D, Matthews H, Moore DJ, Mursaleen L, Schwarzschild MA, Stott SRW, Sulzer D, Svenningsson P, Tanner CM, Carroll C, Simon DK, Brundin P. Wyse RK, et al. Among authors: schwarzschild ma. J Parkinsons Dis. 2024 Apr 5. doi: 10.3233/JPD-230363. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38578902 Review.
Incidence of Parkinson disease in North America.
Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, Van Den Eeden SK, Tanner CM, Marras C; Parkinson’s Foundation P4 Group. Willis AW, et al. NPJ Parkinsons Dis. 2022 Dec 15;8(1):170. doi: 10.1038/s41531-022-00410-y. NPJ Parkinsons Dis. 2022. PMID: 36522332 Free PMC article.
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators; Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C. Schwid SR, et al. Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006. Mov Disord. 2010. PMID: 20669311 Clinical Trial.
Perspectives of People At-Risk on Parkinson's Prevention Research.
Keavney JL, Mathur S, Schroeder K, Merrell R, Castillo-Torres SA, Gao V, Crotty GF, Schwarzschild MA, Poma JM. Keavney JL, et al. Among authors: schwarzschild ma. J Parkinsons Dis. 2024;14(3):399-414. doi: 10.3233/JPD-230436. J Parkinsons Dis. 2024. PMID: 38489198 Free PMC article. Review.
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators; Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Schwarzschild MA, et al. Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14. Arch Neurol. 2008. PMID: 18413464 Free PMC article. Clinical Trial.
Mitochondrial haplogroups and cognitive progression in Parkinson's disease.
Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Ravina B, Shoulson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium. Liu G, et al. Among authors: schwarzschild ma. Brain. 2023 Jan 5;146(1):42-49. doi: 10.1093/brain/awac327. Brain. 2023. PMID: 36343661 Free PMC article.
244 results